ArticleVirchows Archiv : an international journal of pathology2007
Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer.
Article in Virchows Archiv : an international journal of pathology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- The role of the PTEN/PI3K/Akt pathway on prognosis in epithelial ovarian cancer: a meta-analysis.The oncologist · 2014Pooled it
- Unveiling Isorhapontigenin's therapeutic potential in lung cancer via integrated network pharmacology, molecular docking, and experimental validation.Scientific reports · 2025Article
- Review
- Correlation between SNPs of PIK3CA, ERBB2 3'UTR, and their interactions with environmental factors and the risk of epithelial ovarian cancer.Journal of assisted reproduction and genetics · 2021Article
- Endometriosis and ovarian cancer risk, an epigenetic connection.Annals of translational medicine · 2020Review
- Genomic Alterations as Potential Therapeutic Targets in Extramammary Paget's Disease of the Vulva.JCO precision oncology · 2020Article
- Comparing PI3K/Akt Inhibitors Used in Ovarian Cancer Treatment.Frontiers in pharmacology · 2020Article
- Akt inhibitor SC66 promotes cell sensitivity to cisplatin in chemoresistant ovarian cancer cells through inhibition of COL11A1 expression.Cell death & disease · 2019Article
- Expression of pAkt is associated with a poor prognosis in Chinese women with invasive ductal breast cancer.Oncology letters · 2018Article
- Prognostic significance of phosphoinositide 3-kinase p110α and p110β isoforms in non-small cell lung cancer.International journal of clinical and experimental pathology · 2018Article
- EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature review.Genes & cancer · 2017Article
- Opposing roles of PIK3CA gene alterations to EZH2 signaling in non-muscle invasive bladder cancer.Oncotarget · 2017Article
- Increased Expression of Phosphatidylinositol 3-Kinase p110α and Gene Amplification of PIK3CA in Nasopharyngeal Carcinoma.Pathology oncology research : POR · 2016Article
- Network-based survival-associated module biomarker and its crosstalk with cell death genes in ovarian cancer.Scientific reports · 2015Article
- Expression of phosphorylated Akt and hTERT is associated with prognosis of epithelial ovarian carcinoma.International journal of clinical and experimental pathology · 2015Article
- Ubiquitin-conjugating enzyme 9 promotes epithelial ovarian cancer cell proliferation in vitro.International journal of molecular sciences · 2013Article
- Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer.The American journal of pathology · 2013Article
- Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma.PloS one · 2013Article
- Mutation and genomic amplification of the PIK3CA proto-oncogene in pituitary adenomas.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2012Article
- The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.Molecular cancer therapeutics · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Disrupted phosphatidylinositol 3-kinase (PI3K) activity and its effect on the downstream target AKT plays an important role in malignant diseases. Gain and/or amplification of PIK3CA gene, encoding the catalytic subunit of phosphatidylinositol 3-kinase (p110 alpha) and its increased expression are associated with enhanced PI3K activity in ovarian cancer cell lines. In this study, ovarian carcinomas with documented clinical outcome were assessed for genetic aberrations at the 3q26.3 locus, including PIK3CA, by fluorescence in situ hybridization. PIK3CA amplification was evaluated by quantitative real-time PCR with respect to a control gene situated at 3q13. The expression of p110 alpha, phosphorylated AKT (pAKT) and the proliferation marker Ki-67 were immunohistochemically investigated. PIK3CA amplification and Ki-67 index were strong predictors for an early tumour-associated death. p110 alpha expression correlated with 3q26.3 gain and Ki-67 index but not with the patient outcome. No relationship could be observed between p110 alpha and pAKT or between pAKT and disease outcome. It is interesting to note that cases with a nuclear pAKT immunoreactivity showed a trend of improved overall survival. Our results underline the prognostic significance of PIK3CA in ovarian carcinoma and argue against a simple linear model of PIK3CA gain/amplification followed by PI3K activation and consecutive AKT phosphorylation in ovarian carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.